COMPASS Pathways

Recent Finacing

Equity

Recent Raise

$285.1M

COMPASS Pathways develops COMP360, a synthetic psilocybin therapy with psychological support for treatment‑resistant depression, running multi‑country randomized phase 3 trials and phase 2 studies in PTSD and anorexia